Saturday 17 October 2026
Export KLRS’s income statement to Excel — free account
Kalaris Therapeutics Inc.
KLRS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 21.3% and free cash flow grew 11.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.00
0.19
−8.68%
Follow KLRS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (79.91%) | (66.60%) | 488.01% | (68.06%) |
+8 more TTM periods Free account |
|
| (46.02%) | (41.43%) | (67.93%) | (54.46%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(50.77%) | (48.79%) | (39.82%) | (76.91%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.72) | (1.79) | (2.50) | (2.10) | |
Free Cash Flow |
(41.02) | (42.51) | (38.23) | (39.30) | |
Capital Expenditures |
— | — | 0.14 | (0.13) | |
| Other line items | |||||
Cash ROIC |
(27.13%) | (25.64%) | (19.43%) | (33.06%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.93 | 0.96 | 0.88 | 0.71 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | (0.86) | (0.58) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.72) | (1.79) | (2.51) | (2.09) | |
Capex per Share |
0.00 | 0.00 | 0.01 | (0.01) | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates